Websites:
http://www.fda.gov
http://www.cms.hhs.gov
The National Forum on Biomedical Imaging in Oncology (NFBIO) was created in 1999 to facilitate partnerships between researchers, the imaging industry, and government agencies. The goal is to address new biomedical opportunities and challenges in oncology and to focus on the regulatory, coverage, and reimbursement issues for established technologies to improve patient diagnosis and care. The forums are cosponsored by NCI, the National Electrical Manufacturers Association (NEMA), FDA, and CMS. The sixth NFBIO took place April 7–8, 2005, and focused on quantitative oncologic imaging. The speakers’ presentations and other information are available on the NFBIO Website: http://imaging.cancer.gov/NewsAndMeetings/meetings.
The Interagency Council on Biomedical Imaging in Oncology (ICBIO), with its next meeting set for October 17, 2006, brings representatives of NCI, FDA, and CMS together with technology developers to expedite the launch of new imaging products. \ The council’s representatives provide advice on the spectrum of scientific, regulatory, and reimbursement issues related to developing an imaging device or technology. Any business or academic investigator who develops a technology relevant to biomedical imaging in cancer may submit a request. Investigators typically meet with the council for approximately one hour for an informal and confidential discussion. More information is available on the council’s Website: http://imaging.cancer.gov/programsandresources/specializedinitiatives/ICBIO.
CIP and FDA have an interagency agreement to develop databases for evaluating image-processing methods for cancer screening, diagnosis, and treatment. The collaboration seeks to develop: